Trials / Completed
CompletedNCT00319787
Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
A Randomized Placebo Controlled Study to Assess the Rate of PSA Decrease, Anatomical & Metabolic Changes in the Prostate Determined by MRI/3D-MRS & Histological Changes by Biopsy in Subjects With Locally Advanced Prostate Carcinoma Treated With Either Casodex® (Bicalutamide) Alone or the Combination of Casodex® & ZD1839 (Iressa™)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 102 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a difference in the rate of decrease of prostate specific antigen (PSA) levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iressa |
Timeline
- Start date
- 2003-12-01
- Completion
- 2006-08-01
- First posted
- 2006-04-27
- Last updated
- 2011-01-25
Locations
3 sites across 1 country: Norway
Source: ClinicalTrials.gov record NCT00319787. Inclusion in this directory is not an endorsement.